GERD — Diagnosis and Management Guideline
Source: ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease — American Journal of Gastroenterology, 2022
Guideline: Strong
Guideline: Conditional
Guideline: Not recommended
ClinicoQ pathway suggestion (not from the cited guideline)
Diagnosis
Diagnostic criteria
Diagnosed clinically in patients with classic symptoms of heartburn and regurgitation; confirmed objectively by endoscopic evidence of mucosal injury or abnormal esophageal acid exposure on reflux monitoring when needed.
⚠ Alarm features (investigate before diagnosing)
- Dysphagia or odynophagia
- GI bleeding or iron deficiency anemia
- Unintentional weight loss
- Recurrent vomiting
- Multiple risk factors for Barrett''s esophagus
Initial workup
| Test | When to order |
|---|---|
| Empiric PPI trial (no endoscopy first) | Classic symptoms without alarm features — first step. |
| Upper endoscopy | Dysphagia, alarm symptoms, or multiple Barrett''s risk factors. |
| Ambulatory reflux monitoring (pH/impedance) | Atypical/extraesophageal symptoms alone, before a PPI trial. |
Treatment
Classic symptoms, no alarm features
1
Once-daily PPI (e.g., omeprazole)
Strong (Guideline recommendation)
- Dose
- 20–40 mg once daily, taken 30–60 minutes before a meal
- Duration
- 8-week empiric trial
- Evidence level
- High
- Avoid if
- —
- If no response ClinicoQ pathway
- Re-evaluate the diagnosis; consider endoscopy or reflux monitoring if symptoms persist
Severe esophagitis (LA grade C/D)
1
Indefinite maintenance PPI therapy or antireflux surgery
Strong (Guideline recommendation)
- Dose
- Maintenance PPI at effective dose, or surgical referral
- Duration
- Long-term/indefinite
- Evidence level
- High
- Avoid if
- —
- If no response
- —
Lifestyle (all patients)
1
Weight loss
Strong (Guideline recommendation) — for overweight/obese patients
- Dose
- —
- Duration
- Ongoing
- Evidence level
- Moderate
- Avoid if
- —
- If no response
- —
✕ Treatments the guideline advises against
Baclofen: Guideline: do not recommend in the absence of objective evidence of GERD (strong recommendation).
Prokinetic agents of any kind: Guideline recommends against use unless there is objective evidence of gastroparesis (strong recommendation).
Sucralfate: Guideline does not recommend for GERD therapy except during pregnancy (strong recommendation).
⚠️ This is an educational summary of current international clinical practice guidelines and does not replace individualized clinical judgment. Final treatment decisions remain the responsibility of the treating physician.